Fingolimod (Gilenya) for 'relapsing-remitting multiple sclerosis’

In a direct comparison of fingolimod with interferon beta (Avonex) in ambulatory patients with relapsing-remitting multiple sclerosis (RMMS), the efficacy of fingolimod in reducing the annual relapse rate was statistically significant, though there was no statistically significant difference in the effect on disease progression.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.